NASDAQ$BBNX
Beta Bionics Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
Beta Bionics reported Q3 2025, revenue of $45M, net loss of $25M.
For Q3 2025, Beta Bionics reported revenue of $45M, a net loss of $25M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $45M.
- Net loss $25M.
- Beta Bionics highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Beta Bionics Inc · Revenue · Quarterly
$27.3M
Forward guidance
The release discusses Beta Bionics's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Beta Bionics cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q3 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q3 2025
-0.7%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+18.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+4.8%
Q2 2025
Best reaction
-5.0%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -13.5% | -17.7% | |
| Q4 2025 | -2.6% | -1.5% | -23.4% | |
| Q3 2025 | +2.2% | +14.6% | +29.9% | |
| Q2 2025 | +4.8% | +17.2% | +33.7% | |
| Q1 2025 | -2.8% | +19.4% | +67.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro